Other languages HAV Group ASA

Equities

HAV

NO0010931918

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-17 am EDT			5-day change	1st Jan Change
9.2 ^NOK	+0.88%		0.00%	-1.08%

Mar. 18	NASDAQ - ADDITIONALLY, ANY UNACKNOWLEDGED ORDERS ON RASH FIX HAV…	RE
Mar. 15	HAV Group ASA Provides Earnings Guidance for 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NASDAQ - ADDITIONALLY, ANY UNACKNOWLEDGED ORDERS ON RASH FIX HAV…	Mar. 18
HAV Group ASA Provides Earnings Guidance for 2024	Mar. 15
HAV Group ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
HAV Group ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13
Havilah Resources Intersects Copper, Gold at Eurinilla Dome	Mar. 08
Hav Group?s Ship Design Business Has Signs Contract to Design and Develop Four Newbuild, Autonomous Zero-Emission Ferries That Will Operate the Lavik-Oppedal Crossing on the Northwest Coast of Norway	Mar. 01
Wilson Chooses HAV Group's Water Treatment Business to Deliver the Ballast Water Treatment Systems to Six 3,800 dwt Newbuilds	Feb. 15
HAV Group Unit Bags Water Treatment Systems Supply Contract	Feb. 15
HAV Group Unit Gets NOK12 Million Funding for Hydrogen Energy System Prototype	Feb. 13
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Feb. 09
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	Feb. 09
HAV Group Finalizes Deal to Develop Offshore Wind Service Operation Vessel for Esvagt	Jan. 19
Havilah Resources Intersects Mineral System at Birksgate Prospect	Jan. 15
SAINSBURY'S CEO:WORKING WITH UK GOVERNMENT ON RED SEA ISSUE, HAV…	Jan. 10
HAV Group ASA Partner for Development of New Vessel	Jan. 08
HAV Group Chosen as Partner to Develop Offshore Vessel	Jan. 08
TEAMSTERS SAY TEAMSTERS WORKING NATIONWIDE AT ANHEUSER-BUSCH HAV…	Dec. 16
Humacyte Seeks FDA Approval of Bioengineered Tissue for Treatment of Vascular Injuries	Dec. 12
HAV Group ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages HAV Group ASA

Equities

HAV

NO0010931918

Other languages

Filters